Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. Umbralisib

   TG THERAPEUTICS, INC.

   Chronic Lymphocytic Leukemia

   phase 2 · small molecule · completed

   4 trials →

2. Umbralisib

   TG THERAPEUTICS, INC.

   Lymphoma

   phase 2 · small molecule · terminated

   1 trial →

3. Utidelone

   Xiyuan Hospital of China Academy of Chinese Medical Sciences

   Breast Cancer

   phase 2 · small molecule · active

   1 trial →

4. V940-005

   Merck Sharp and Dohme

   Muscle-invasive Urothelial Carcinoma

   phase 2 · small molecule · active

   1 trial →

5. V940-012

   Merck Sharp and Dohme

   Melanoma

   phase 2 · small molecule · active

   1 trial →

6. V940-013

   Merck Sharp and Dohme

   Non-small cell lung cancer stage IV

   phase 2 · small molecule · active

   1 trial →

7. VACl

   The First People's Hospital of Lianyungang

   Acute Myeloid Leukemia, Adult

   phase 2 · small molecule · active

   1 trial →

8. VATS

   The First People's Hospital of Lianyungang

   Non-small Cell Lung Cancer

   phase 2 · other · active

   1 trial →

9. VCAR33

   Vor Biopharma

   Leukemia, Myeloid, Acute

   phase 2 · mab · terminated

   1 trial →

10. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Kaposi's Sarcoma

    phase 2 · small molecule · terminated

    1 trial →

11. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Adult T-cell Leukemia/Lymphoma

    phase 2 · small molecule · active

    1 trial →

12. VEN (Venetoclax)

    The First People's Hospital of Lianyungang

    Myelodysplastic Neoplasms

    phase 2 · small molecule · active

    1 trial →

13. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 · small molecule · active

    1 trial →

14. VESPA

    Fondazione Telethon ETS

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 2 · small molecule · active

    1 trial →

15. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Anal Neoplasm

    phase 2 · mab · completed

    1 trial →

16. VHIO19001

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 · small molecule · active

    1 trial →

17. VHIO23001

    The George Institute

    Metastatic colorectal cancer

    phase 2 · small molecule · active

    1 trial →

18. VHIO23002

    The George Institute

    Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

    phase 2 · small molecule · active

    1 trial →

19. VHIO24002

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 · small molecule · active

    1 trial →

20. VINORELBINE for Hodgkin’s lymphoma

    Fondazione Telethon ETS

    Hodgkin’s lymphoma

    phase 2 · small molecule · active

    1 trial →

21. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 · small molecule · active

    1 trial →

22. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 · small molecule · terminated

    1 trial →

23. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 · mab · terminated

    1 trial →

24. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 · small molecule · active

    1 trial →

25. VV1

    Regeneron UK Limited

    Melanoma

    phase 2 · mab · active

    1 trial →

26. VX15/2503 + avelumab

    VACCINEX, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 · small molecule · completed

    1 trial →

27. Vaccine

    Atrium Therapeutics

    Pediatric Cancer

    phase 2 · mab · active

    1 trial →

28. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 · small molecule · active

    1 trial →

29. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 · small molecule · active

    1 trial →

30. Vebreltinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable MET-altered Non-Small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

31. Vectibix /ml concentrate for RAS/BRAF wild-type metastatic c…

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 · small molecule · active

    1 trial →

32. Vel-FC-4003

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma Recurrent

    phase 2 · small molecule · active

    1 trial →

33. Venetoclax

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 · small molecule · active

    1 trial →

34. Venetoclax

    The First People's Hospital of Lianyungang

    Early T Acute Lymphoblastic Leukemia

    phase 2 · small molecule · active

    1 trial →

35. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 · small molecule · terminated

    1 trial →

36. Venetoclax

    The First People's Hospital of Lianyungang

    Acute Leukemia of Ambiguous Lineage

    phase 2 · small molecule · active

    1 trial →

37. Venetoclax

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 · small molecule · active

    1 trial →

38. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 · small molecule · active

    1 trial →

39. Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 · small molecule · terminated

    1 trial →

40. Venetoclax, Azacitidine

    The First People's Hospital of Lianyungang

    T-cell Acute Lymphoblastic Leukemia

    phase 2 · small molecule · active

    1 trial →

41. Venetoclax；Azacitidine；Homoharringtonine

    The First People's Hospital of Lianyungang

    Secondary Acute Myeloid Leukemia

    phase 2 · small molecule · active

    1 trial →

42. Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

    phase 2 · small molecule · active

    1 trial →

43. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 · small molecule · active

    1 trial →

44. Vincristine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Precursor Cell Lymphoblastic Leukemia-Lymphoma

    phase 2 · small molecule · active

    1 trial →

45. Vinflunine

    United Therapeutics Europe Ltd

    Locally-advanced or Metastatic Penile Neoplasms

    phase 2 · small molecule · completed

    1 trial →

46. Vitamin D

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 · small molecule · terminated

    1 trial →

47. Vociprotafib

    Revolution Medicines

    Metastatic Neoplasm

    phase 2 · small molecule · terminated

    1 trial →

48. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 · mab · active

    1 trial →

Frequently asked questions